Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 348 Results
Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
December 10, 2015
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015
November 12, 2015
Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results; Teleconference and Webcast to be held on November 12, 2015
November 10, 2015
Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart Failure Society of America Annual Meeting
September 28, 2015
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results
September 21, 2015
Palatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction
September 21, 2015
Palatin Technologies Supports FDA’s Approval of the First-Ever Treatment for Female Sexual Dysfunction
August 18, 2015
Palatin Technologies Completes $30 Million Financing
July 6, 2015
Page 24 of 35